Hualan Biological’s investee company’s application for marketing authorization of adalimumab injection has been accepted
January 15, 2026
Source: drugdu
86
On January 13, Hualan Biological Engineering Co., Ltd.The company issued an announcement regarding its investee company, Hualan Ankang Biotechnology Co., Ltd.The company (formerly known as Hualan Gene Engineering Co., Ltd.) has received the Acceptance Notice (Acceptance No.: CXSS2600006) from the National Medical Products Administration for its application for registration and marketing authorization of adalimumab injection for domestic production. This drug is a biosimilar used to treat various autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease.
The announcement stated that, as of now, Shenzhou Cell has [a certain number of] [products/services] in China.Adalimumab injection from eight companies, including an engineering company, has been approved for marketing. If Hualan Ankang's product is ultimately approved for marketing, it will enrich its product portfolio and is expected to add a new profit growth point.
https://finance.eastmoney.com/a/202601133616721398.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Kanghua Biologics Faces Formidable Challenges in mRNA Vaccine Development February 6, 2026
- Aligning with international standards! Aidea Pharma obtains Tanzania’s ML3 GMP certification February 5, 2026
- Shijiazhuang Pharmaceutical Group’s clopidogrel emulsion injection has received a drug registration certificate. February 5, 2026
- Human Coagulation Factor IX Drug Registration and Marketing Authorization Application Accepted February 5, 2026
- HX111 completes first patient dosing in Phase I clinical trial February 5, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
